¹⁷⁷Lu-FAP-2286 — Investigational Agent
Radiopharmaceutical · Phase 1/2 · Novartis
Mechanism of Action
A fibroblast activation protein (FAP)-targeted peptide radioconjugate labeled with lutetium-177 that delivers beta-emitting radiation to FAP-expressing cancer-associated fibroblasts and tumor stroma across multiple solid tumor types.
Investigational Indications
- FAP-expressing advanced solid tumors
- Pancreatic cancer
- Sarcoma